A multiple-dose, non-randomized, open-label, multicenter study to evaluate the long-term safety and effectiveness of EN3267 [Abstral, Rapinyl; Endo Pharmaceuticals] [fentanyl] in the treatment of breakthrough pain in cancer patients

Trial Profile

A multiple-dose, non-randomized, open-label, multicenter study to evaluate the long-term safety and effectiveness of EN3267 [Abstral, Rapinyl; Endo Pharmaceuticals] [fentanyl] in the treatment of breakthrough pain in cancer patients

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jan 2013

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Endo Pharmaceuticals; ProStrakan
  • Most Recent Events

    • 09 Jun 2009 Actual patient number (97) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 09 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top